Inventor · Neipu, TW

Ann Chen

17Patents
1h-index
26Co-inventors
50Inventor score

Filing activity: Jun 17, 2009 → Oct 29, 2020

Most-cited inventions

PatentTitleAreaCited byStatus
US9844560B2 Use of ginsenoside M1 for treating lupus nephritis Human Necessities 3 Active
US10172876B2 Use of ginsenoside M1 for treating IgA nephropathy Human Necessities 1 Active
US8178358B2 Serpine2 as a biomarker for IgA nephropathy Physics 0 Active
US8329410B2 Method for diagnosing kidney disease comprising detecting the level of annexin A2 Physics 0 Active
US9475789B2 Use of polyenylpyrrole derivatives for treating inflammation Human Necessities 0 Active
US9295705B2 Treatment for nephritis Human Necessities 0 Active
US12090132B2 Tris DBA pharmaceutical composition and its use for treating autoimmune diseases Human Necessities 0 Active
US9393226B2 Use of osthole for treating focal segmental glomerulosclerosis Human Necessities 0 Active
US8414938B2 Schisandrae fructus extracts for inhibition or prevention of H1N1 influenza virus infection and its application thereof Human Necessities 0 Active
US8993637B2 Use of citral for treating focal segmental glomerulosclerosis Human Necessities 0 Active
US8785137B2 Method for renal disease diagnosis using Rab23 as marker Chemistry; Metallurgy 0 Active
US8518461B2 Use of bamboo vinegar for treating inflammation Human Necessities 0 Active
US9321795B2 Use of hydroxycinnamaldehyde glycoside derivatives for treating glomerulonephritis Human Necessities 0 Active
US8329651B2 Method for renal disease diagnosis and prognosis using annexin A1 and Rab23 as markers Chemistry; Metallurgy 0 Active
US11834647B2 In vitro immune synapse system and method of in vitro evaluating immune response using the same Physics 0 Active
US12000841B2 Diagnostic kits and methods configured to rapidly and non-invasively determine physiologic levels of galactose-deficient IgA1 (Gd-IgA1) in the subject of IgA nephropathy Physics 0 Active
US10357507B2 Use of ginsenoside M1 for inhibiting renal fibrosis Human Necessities 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.